Figure 2.
Outcomes for patients with ITDpos according to cooccurring risk groups of FR mutation, INT, or PR mutations. (A) 5-year EFS, (B) 5-year OS, and (C) 5-year relapse risk.
Outcomes for patients with ITDpos according to cooccurring risk groups of FR mutation, INT, or PR mutations. (A) 5-year EFS, (B) 5-year OS, and (C) 5-year relapse risk.
